Cadila Healthcare receives EIR from USFDA, Share Prices Rise by 2.5%
Shital Jibhe / 06 Jun 2017
Cadila Healthcare formulations facility at Baddi has received an Establishment Inspection Report (EIR) from the USFDA, the company informed on Monday.
Cadila Healthcare formulations facility at Baddi has received an Establishment Inspection Report (EIR) from the USFDA, the company informed on Monday.
Cadila Healthcare Limited is a well-known research-oriented, technology-driven pharmaceutical company focused on the research areas of biotechnology, formulations and Active Pharmaceutical Ingredients.
Zydus Cadila has received final approval from the USFDA for Mirtazapine Orally Disintegrating Tablets USP of 15 mg, 30 mg and 45 mg, the company further said.
Meanwhile, Cadila Healthcare on Tuesday was up by 2.5% at Rs 503 per share at 0957 hours IST on BSE. The stock touched a high of Rs 510 and a low of Rs 500.80 in the morning hours.
The stock has delivered over 55% returns in a year’s time. It has outperformed BSE Sensex and BSE Healthcare over the same period.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.